Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.60 |
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.60 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15604350 | 0.93 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL3415389 | 0.91 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL17099717 | 0.90 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL501442 | 0.89 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL20879065 | 0.89 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL15525995 | 0.89 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL2814577 | 0.89 | HSP90AB1 (0.59) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL15525969 | 0.88 | HSP90AB1 (0.55) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL15525975 | 0.87 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| Ganetespib SCHEMBL421080 | 0.86 | HSP90AA1 (0.77) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| EP-3738594-A1 | TARGETED THERAPEUTICS HAVING AN HSP90 LIGAND AS BINDING MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10828315-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200316090-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2020-10-08 | — | — | US | disclosed |
| EP-3035938-B1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10722525-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10675360-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| CN-110559446-A | Targeted therapeutics | 马德里加尔制药公司 | 2019-12-13 | — | — | CN | disclosed |
| EP-3466416-A2 | A BINDING MOIETY-DRUG CONJUGATE COMPRISING A HSP90 BINDING MOIETY AND A CYTOTOXIC EFFECTOR MOIETY | Madrigal Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10232049-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3129064-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015143004-A9 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-3035938-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015143004-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015134464-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150139905-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2838909-A2 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20140079636-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2014-03-20 | — | — | US | disclosed |
| WO-2013158644-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316090-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-20210085700-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-20150139905-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-10675360-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-10232049-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-10722525-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-10828315-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
| US-20140079636-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | HSP90AA1 5/4885HSP90AB1 2/4885HSP90B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.